+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CAR-T Cell Therapy Market by Target Indications, Target Antigens, Key Players and Key Geographies - Global Forecast 2022-2035

  • PDF Icon

    Report

  • 640 Pages
  • October 2022
  • Region: Global
  • Roots Analysis
  • ID: 5691623

Quick Summary:

The Cancer industry is on the cusp of a revolution thanks to the promising developments in CAR-T cell therapies. As the disease continues to exert physical, emotional, and financial burdens worldwide, the search for more effective treatments has never been more imparted. Our comprehensive market research report offers critical insights into the future potential of CAR-T cell therapies, featuring the strides made by industry players and academic organizations in this rapidly evolving sector.

There is significant growth projected for the CAR-T cell therapy market driven by continuous innovations, substantial financial support from investors, and encouraging clinical trial results. With over 5 CAR-T therapies already approved for several hematological malignancies and over 170 companies engaged in the development of early and late-stage CAR-T therapies worldwide, the investment future in this sector looks promising. The report examines factors shaping CAR-T cell therapy's pricing, promotional strategies adopted by successful developers, and in-depth profiles of the leading players in this landmark report.

The cancer is the one of the leading cause of deaths, globally. In fact, as per the World Health Organization (WHO), 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities as well as the national health systems. Even though a number of treatment options are available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is still difficult to achieve. Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR-T cell therapy, a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. Overall, this highly specific and promising form of CAR-T cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. 

At present, more than 5 CAR-T therapies have been approved for several hematological malignancies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences), Breyanzi® (Bristol Myers Squibb), Abecma™ (Bristol Myers Squibb) and CARVYKTI™ (Janssen Biotech / Legend Biotech). In fact, more than 170 companies are engaged in the development of over 970 early and late-stage CAR-T therapies, worldwide. Moreover, several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. Over 6,500 patents related to CAR-T cell therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, more than 260 collaborations have been inked between several industry / academic stakeholders in order to advance the development of various pipeline candidates. To fund product development initiatives, capital investments worth more than USD 24 billion have been made by various private and public sector investors, in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the CAR-T cell therapy market is likely to witness significant growth in the foreseen future.

Scope of the Report

The “CAR-T Cell Therapy Market (4th Edition) by Target Indications (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis And Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19 / CD22, EGFR, NY-ESO-1 and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of CAR-T-cell immunotherapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).
  • An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
  • A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
  • An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies, considering them to be KOLs, who are actively involved in R&D of CAR-T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
  • Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
  • An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents. 
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell based immunotherapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapies (Kimmtrak®).
  • Elaborate profiles of the several leading players in the domain of CAR-T cell therapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T cell therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for CAR-T cell therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of CAR-T cell therapies that are already marketed or in the late stages of development. Additionally, it features market size projections for the overall CAR-T cell therapy market, wherein opportunity has been segmented across [A] target indications (non-hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma), [B] target antigens (CD19, BCMA, CD19 / CD22 and others), Key Players and [C] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain.

The report features detailed transcripts of interviews held with the following individuals:

  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the prevalent R&D trends related to CAR-T cell therapies?
  • Which different types of clinical conditions can be treated using CAR-T cell therapies?
  • Who are the leading industry and non-industry players in this market?
  • In which geographies, extensive research on CAR-T cell therapy is being conducted?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • Who are the key investors in the CAR-T cell immunotherapy domain? 
  • Who are the key opinion leaders / experts from renowned academic and research institutes which can help drive product development efforts in this domain?
  • How is the intellectual property landscape for global CAR-T cell therapies likely to evolve in the foreseen future?
  • Who are the key service providers (CMOs / CDMOs) with capabilities to develop and manufacture CAR-T cell therapies?
  • What are the key factors that are likely to influence the evolution of the CAR-T cell immunotherapies market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the key promotional strategies used by companies having marketed products?

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. PREFACE
1.1. Chapter Overview
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapy
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3.  By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3.7.1. Development History
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane (TM) Domain
3.7.2.3. Endodomain
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration
3.7.6. Case Study on CD19 CAR-T Cell Therapies
3.7.6.1. Other Important Biological Targets for CAR Development
3.7.7. Challenges Associated with CAR-T Cell Therapies
3.7.7.1. Competitive Risks
3.7.7.2. Clinical Risks
3.7.7.3. Regulatory Risks
3.7.7.4. Commercial Risks
3.8. Concluding Remarks

4. CAR-T CELL THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Key Target Indication
4.2.6. Analysis by Key Target Antigen
4.2.7. Analysis by Source of T-Cells
4.2.8. Analysis by Phase of Development and Source of T-Cells
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Dosing Frequency
4.2.11. Analysis by Target Patient Segment
4.2.12. Analysis by Type of Therapy
4.2.13. Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
4.2.14. Most Active Non-Industry Players: Analysis by Number of CAR-T Cell Therapies
4.3. CAR-T Cell Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. CAR-T Cell Therapies: Competitive Analysis of Popular Target Antigens
5.2.1. Popular Targets Related to Hematological Malignancies
5.2.2. Popular Targets Related to Solid Tumors
5.3. T-Cell Immunotherapies: CAR Construct Analysis
5.3.1. Analysis by Generation of CAR
5.3.2. Analysis by Type of scFv Antibody
5.3.3. Analysis by Type of Virus Used
5.3.4. Analysis by Type of Gene Transfer Method Used
5.3.5. Analysis by Type of Co-Stimulatory Domain

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CAR-T Cell Therapies: Clinical Trial Analysis
6.3.1. Analysis of Trials by Trial Registration Year
6.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
6.3.3. Analysis by Trial Status
6.3.4. Analysis by Trial Registration Year and Trial Status
6.3.5. Analysis by Trial Phase
6.3.6. Analysis of Enrolled Patient Population by Trial Phase
6.3.7. Analysis by Target Patient Segment
6.3.8. Analysis by Type of Sponsor / Collaborator
6.3.9. Analysis by Study Design
6.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.12. Analysis by Key Focus Areas
6.3.13. Analysis of Trials by Geography
6.3.14. Analysis of Enrolled Patient Population by Geography

7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. CAR-T Cell Therapies: Key Opinion Leaders
7.4.1. Analysis by Type of Organization
7.4.2. Analysis by Affiliated Organization
7.4.3. Analysis by Qualification
7.4.4. Analysis by Geographical Location of KOLs
7.4.5. KOL Activeness versus KOL Strength
7.4.6. Most Prominent KOLs: Analysis by RA score
7.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. Clinical Trial Information
8.2.3. Clinical Trial Endpoints
8.2.4. Clinical Trial Results
8.2.5. Estimated Sales Revenues
8.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
8.3.1. Therapy Overview
8.3.2. Clinical Trial Information
8.3.3. Clinical Trial Endpoints
8.3.4. Clinical Trial Results
8.3.5. Estimated Sales Revenues
8.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
8.4.1. Therapy Overview
8.4.2. Clinical Trial Information
8.4.3. Clinical Trial Endpoints
8.4.4. Clinical Trial Results
8.4.5. Estimated Sales Revenues
8.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers     Squibb)
8.5.1. Therapy Overview
8.5.2. Clinical Trial Information
8.5.3. Clinical Trial Endpoints
8.5.4. Clinical Trial Results
8.5.5. Estimated Sales Revenues
8.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
8.6.1. Therapy Overview
8.6.2. Clinical Trial Information
8.6.3. Clinical Trial Endpoints
8.6.4. Clinical Trial Results
8.6.5. Estimated Sales Revenues
8.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
8.7.1. Therapy Overview
8.7.2. Clinical Trial Information
8.7.3. Clinical Trial Endpoints
8.7.4. Clinical Trial Results
8.7.5. Estimated Sales Revenues
8.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
8.8.1. Therapy Overview
8.8.2. Clinical Trial Information
8.8.3. Clinical Trial Endpoints
8.8.4. Clinical Trial Results
8.8.5. Estimated Sales Revenues
8.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
8.9.1. Therapy Overview
8.9.2. Clinical Trial Information
8.9.3. Clinical Trial Endpoints
8.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
8.10.1. Therapy Overview
8.10.2. Clinical Trial Information
8.10.3. Clinical Trial Endpoints
8.10.4. Clinical Trial Results
8.10.5. Estimated Sales Revenues
8.11. AUTO3 / CD19/22 CAR-T (Autolus)
8.11.1. Therapy Overview
8.11.2. Clinical Trial Information
8.11.3. Clinical Trial Endpoints
8.11.4. Clinical Trial Results
8.11.5. Estimated Sales Revenues

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. CAR-T Cell Therapies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year of Partnership and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Most Popular Products: Analysis by Number of Partnerships
9.3.6. Most Active Industry Players: Analysis by Number of Partnerships
9.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
9.3.8. Analysis by Geography
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. International and Local Deals

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. CAR-T Cell Therapies: Funding and Investment Analysis
10.3.1. Analysis of Instances by Year
10.3.2. Analysis of Amount Invested by Year
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Type of Investor
10.3.5. Most Active Players: Analysis by Number of Instances
10.3.6. Most Active Investors: Analysis by Amount Invested
10.3.7. Analysis of Amount Invested by Geography
10.3.8. Most Active Investors: Analysis by Number of Funding Instances

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. CAR-T Cell Therapies: Patent Analysis
11.3.1. Analysis by Patent Publication Year
11.3.2. Analysis by Patent Application Year
11.3.3. Analysis by Geography
11.3.4. Analysis by Type of Player
11.3.5. Analysis by CPC Symbols
11.3.6. Analysis by Key Focus Area
11.3.7. Leading Players: Analysis by Number of Patents
11.3.8. CAR-T Cell Therapies: Patent Benchmarking
11.3.9. Analysis By Patent Characteristics
11.3.10. CAR-T Cell Therapies: Patent Valuation

12. CASE STUDY: CELL THERAPY MANUFACTURING
12.1. Chapter Overview
12.2. Overview of Cell Therapy Manufacturing
12.3. Cell Therapy Manufacturing Models
12.3.1. Centralized Manufacturing Model
12.3.2. Decentralized Manufacturing Model
12.4. Scalability of Cell Therapy Manufacturing Processes
12.4.1. Scale-Up
12.4.2. Scale-Out
12.5. Types of Cell Therapy Manufacturers
12.6. Key Challenges Related to Manufacturing of Cell Therapies
12.7. Key Considerations for Cell Therapy Manufacturing
12.7.1. Characterization
12.7.2. Cost of Goods
12.8. Automation of Cell Therapy Manufacturing Process
12.9. Cell Therapy Manufacturing Supply Chain
12.10. Comparison of Players Having In-House Capabilities and Contract Manufacturers
12.11. Regulatory Landscape
12.12. Future Perspectives

13. COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing to the High Price of Cell / Gene Therapies
13.3. Pricing Models for T-Cell Immunotherapies
13.3.1. Based on Associated Costs
13.3.2. Based on Availability of Competing Products
13.3.3. Based on Patient Segment
13.3.4. Based on Opinions of Industry Experts
13.4. Reimbursement related Considerations for T-cell Immunotherapies
13.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Global CAR-T Cell Therapies Market, 2022-2035
14.4.1. CAR-T Cell Therapies Market: Analysis by Target Indication
14.4.2. CAR-T Cell Therapies Market: Analysis by Target Antigen
14.4.3. CAR-T Cell Therapies Market: Analysis by Key Players
14.4.4. CAR-T Cell Therapies Market: Analysis by Geography
14.4.5. Product Wise Sales Forecast
14.4.5.1. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
14.4.5.1.1. Sales Forecast (USD Million)
14.4.5.1.2. Net Present Value
14.4.5.1.3. Value Creation Analysis
14.4.5.2. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
14.4.5.2.1. Sales Forecast (USD Million)
14.4.5.2.2. Net Present Value (USD Million)
14.4.5.2.3. Value Creation Analysis
14.4.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
14.4.5.3.1. Sales Forecast (USD Million)
14.4.5.3.2. Net Present Value (USD Million)
14.4.5.3.3. Value Creation Analysis
14.4.5.4. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
14.4.5.4.1. Sales Forecast (USD Million)
14.4.5.4.2. Net Present Value (USD Million)
14.4.5.4.3. Value Creation Analysis
14.4.5.5. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
14.4.5.5.1. Sales Forecast (USD Million)
14.4.5.5.2. Net Present Value (USD Million)
14.4.5.5.3. Value Creation Analysis
14.4.5.6. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
14.4.5.6.1. Sales Forecast (USD Million)
14.4.5.6.2. Net Present Value (USD Million)
14.4.5.6.3. Value Creation Analysis
14.4.5.7. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
14.4.5.7.1. Sales Forecast (USD Million)
14.4.5.7.2. Net Present Value (USD Million)
14.4.5.7.3. Value Creation Analysis
14.4.5.8. BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.8.1. Sales Forecast (USD Million)
14.4.5.8.2. Net Present Value (USD Million)
14.4.5.8.3. Value Creation Analysis
14.4.5.9. CD19 CAR-T (Wuhan Si'an Medical Technology)
14.4.5.9.1. Sales Forecast (USD Million)
14.4.5.9.2. Net Present Value (USD Million)
14.4.5.9.3. Value Creation Analysis
14.4.5.10. Descartes-11 (Cartesian Therapeutics)
14.4.5.10.1. Sales Forecast (USD Million)
14.4.5.10.2. Net Present Value (USD Million)
14.4.5.10.3. Value Creation Analysis
14.4.5.11. Descartes-08 (Cartesian Therapeutics)
14.4.5.11.1. Sales Forecast (USD Million)
14.4.5.11.2. Net Present Value (USD Million)
14.4.5.11.3. Value Creation Analysis
14.4.5.12. Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine)
14.4.5.12.1. Sales Forecast (USD Million)
14.4.5.12.2. Net Present Value (USD Million)
14.4.5.12.3. Value Creation Analysis
14.4.5.13. CNCT19 / HY001 (Juventas Cell Therapy)
14.4.5.13.1. Sales Forecast (USD Million)
14.4.5.13.2. Net Present Value (USD Million)
14.4.5.13.3. Value Creation Analysis
14.4.5.14. CD30.CAR-T / TT11 (Tessa Therapeutics)
14.4.5.14.1. Sales Forecast (USD Million)
14.4.5.14.2. Net Present Value (USD Million)
14.4.5.14.3. Value Creation Analysis
14.4.5.15. TAK-007 (Takeda)
14.4.5.15.1. Sales Forecast (USD Million)
14.4.5.15.2. Net Present Value (USD Million)
14.4.5.15.3. Value Creation Analysis
14.4.5.16. AUTO1 (Autolus)
14.4.5.16.1. Sales Forecast (USD Million)
14.4.5.16.2. Net Present Value (USD Million)
14.4.5.16.3. Value Creation Analysis
14.4.5.17. AUTO3 (Autolus)
14.4.5.17.1. Sales Forecast (USD Million)
14.4.5.17.2. Net Present Value (USD Million)
14.4.5.17.3. Value Creation Analysis
14.4.5.18. CD19 CAR-T (Bioray Laboratories)
14.4.5.18.1. Sales Forecast (USD Million)
14.4.5.18.2. Net Present Value (USD Million)
14.4.5.18.3. Value Creation Analysis
14.4.5.19. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.19.1. Sales Forecast (USD Million)
14.4.5.19.2. Net Present Value (USD Million)
14.4.5.19.3. Value Creation Analysis
14.4.5.20. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
14.4.5.20.1. Sales Forecast (USD Million)
14.4.5.20.2. Net Present Value (USD Million)
14.4.5.20.3. Value Creation Analysis
14.4.5.21. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
14.4.5.21.1. Sales Forecast (USD Million)
14.4.5.21.2. Net Present Value (USD Million)
14.4.5.21.3. Value Creation Analysis
14.4.5.22. BinD19 (Shenzhen BinDeBio)
14.4.5.22.1. Sales Forecast (USD Million)
14.4.5.22.2. Net Present Value (USD Million)
14.4.5.22.3. Value Creation Analysis
14.4.5.23. CARCIK-CD19 (CoImmune)
14.4.5.23.1. Sales Forecast (USD Million)
14.4.5.23.2. Net Present Value (USD Million)
14.4.5.23.3. Value Creation Analysis
14.4.5.24. PBCAR269A (Precision BioSciences / Servier)
14.4.5.24.1. Sales Forecast (USD Million)
14.4.5.24.2. Net Present Value (USD Million)
14.4.5.24.3. Value Creation Analysis
14.4.5.25. CD123 CAR-T cells Therapy (Chongqing Precision Biotechnology)
14.4.5.25.1. Sales Forecast (USD Million)
14.4.5.25.2. Net Present Value (USD Million)
14.4.5.25.3. Value Creation Analysis
14.4.5.26. BCMA CAR-T (Chongqing Precision Biotech)
14.4.5.26.1. Sales Forecast (USD Million)
14.4.5.26.2. Net Present Value (USD Million)
14.4.5.26.3. Value Creation Analysis
14.4.5.27. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.27.1. Sales Forecast (USD Million)
14.4.5.27.2. Net Present Value (USD Million)
14.4.5.27.3. Value Creation Analysis
14.4.5.28. GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology)
14.4.5.28.1. Sales Forecast (USD Million)
14.4.5.28.2. Net Present Value (USD Million)
14.4.5.28.3. Value Creation Analysis
14.4.5.29. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
14.4.5.29.1. Sales Forecast (USD Million)
14.4.5.29.2. Net Present Value (USD Million)
14.4.5.29.3. Value Creation Analysis
14.4.5.30. ALLO-501A / ALLO-501 (Allogene Therapeutics)
14.4.5.30.1. Sales Forecast (USD Million)
14.4.5.30.2. Net Present Value (USD Million)
14.4.5.30.3. Value Creation Analysis
14.4.5.31. CD19/CD20-CAR-T (Yake Biotechnology)
14.4.5.31.1. Sales Forecast (USD Million)
14.4.5.31.2. Net Present Value (USD Million)
14.4.5.31.3. Value Creation Analysis
14.4.5.32. CD7 CAR-T (PersonGen BioTherapeutics)
14.4.5.32.1. Sales Forecast (USD Million)
14.4.5.32.2. Net Present Value (USD Million)
14.4.5.32.3. Value Creation Analysis
14.4.5.33. Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics)
14.4.5.33.1. Sales Forecast (USD Million)
14.4.5.33.2. Net Present Value (USD Million)
14.4.5.33.3. Value Creation Analysis
14.4.5.34. CT053 (CARsgen Therapeutics)
14.4.5.34.1. Sales Forecast (USD Million)
14.4.5.34.2. Net Present Value (USD Million)
14.4.5.34.3. Value Creation Analysis
14.4.5.35. Anti-ALPP CAR-T Cells (TCRCure Biopharma)
14.4.5.35.1. Sales Forecast (USD Million)
14.4.5.35.2. Net Present Value (USD Million)
14.4.5.35.3. Value Creation Analysis
14.4.5.36. BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology)
14.4.5.36.1. Sales Forecast (USD Million)
14.4.5.36.2. Net Present Value (USD Million)
14.4.5.36.3. Value Creation Analysis
14.4.5.37. ALLO-605 (Allogene Therapeutics)
14.4.5.37.1. Sales Forecast (USD Million)
14.4.5.37.2. Net Present Value (USD Million)
14.4.5.37.3. Value Creation Analysis
14.4.5.38. WU CART 007 (Wugen)
14.4.5.38.1. Sales Forecast (USD Million)
14.4.5.38.2. Net Present Value (USD Million)
14.4.5.38.3. Value Creation Analysis
14.4.5.39. CT103A (Nanjing IASO Biotherapeutics)
14.4.5.39.1. Sales Forecast (USD Million)
14.4.5.39.2. Net Present Value (USD Million)
14.4.5.39.3. Value Creation Analysis

15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website Analysis
15.4. Summary of Patient Support Services and Informative Downloads
15.5. Kymriah®: Promotional Analysis
15.5.1. Drug Overview
15.5.2. Product Website Analysis
15.5.2.1. Message for Healthcare Professionals
15.5.2.2. Message for Patients
15.5.2.3. Informative Downloads
15.5.3. Patient Support Services
15.6. Yescarta®: Promotional Analysis
15.6.1. Drug Overview
15.6.2. Product Website Analysis
15.6.2.1. Message for Healthcare Professionals
15.6.2.2. Message for Patients
15.6.2.3. Informative Downloads
15.6.3. Patient Support Services
15.7. Tecartus®: Promotional Analysis
15.7.1. Drug Overview
15.7.2. Product Website Analysis
15.7.2.1. Message for Healthcare Professionals
15.7.2.2. Message for Patients
15.7.2.3. Informative Downloads
15.7.3. Patient Support Services
15.8. Breyanzi®: Promotional Analysis
15.8.1. Drug Overview
15.8.2. Product Website Analysis
15.8.2.1. Message for Healthcare Professionals
15.8.2.2. Message for Patients
15.8.2.3. Informative Downloads
15.8.3. Patient Support Services
15.9. Abecma®: Promotional Analysis
15.9.1. Drug Overview
15.9.2. Product Website Analysis
15.9.2.1. Message for Healthcare Professionals
15.9.2.2. Message for Patients
15.9.2.3. Informative Downloads
15.9.3. Patient Support Services
15.10. Carvykti®: Promotional Analysis
15.10.1. Drug Overview
15.10.2. Product Website Analysis
15.10.2.1. Message for Healthcare Professionals
15.10.2.2. Message for Patients
15.10.2.3. Informative Downloads
15.10.3. Patient Support Services

16. COMPANY PROFILES
16.1. Chapter Overview
16.2. Alaunos Therapeutics
16.3. Autolus
16.4. Bluebird Bio
16.5. Bristol Myers Squibb
16.6. Carsgen Therapeutics
16.7. Cellectis
16.8. Cellular Biomedicine Group
16.9. Gilead Sciences
16.10. Innovative Cellular Therapeutics
16.11. Kuur Therapeutics
16.12. Noile-Immune Biotech
16.13. Novartis
16.14. Shanghai GeneChem
16.15. Sinobioway Cell Therapy
16.16. Takara Bio
16.17. Wellington Zhaotai Therapies

17. CONCLUDING REMARKS
18 EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Glycostem Therapeutics
18.2.1. Interview Transcript: Troels Jordansen, Chief Executive Officer
18.2. Gracell Biotechnologies
18.2.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer
18.3. TxCell
18.3.1. Interview Transcript: Miguel Forte, Chief Operating Officer
18.4. Kite Pharma
18.4.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
18.5. Celyad
18.5.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
18.6. Waisman Biomanufacturing
18.6.1. Interview Transcript: Brian Dattilo, Manager of Business Development
18.7. Theravectys
18.7.1. Interview Transcript: Aino Kalervo, Former Competitive Intelligence Manager, Strategy & Business Development
18.8. Changhai Hospital
18.8.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
18.9. University of Colorado
18.9.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

19. APPENDIX 1: TABULATED DATA20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Development History of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR-T Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR-T Cell Therapies
Figure 4.1 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 4.2 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 4.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 4.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 CAR-T Cell Therapies: Distribution by Key Target Indication
Figure 4.6 CAR-T Cell Therapies: Distribution by Key Target Antigen
Figure 4.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Figure 4.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cells
Figure 4.9 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 4.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Figure 4.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Figure 4.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 4.13 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Figure 4.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.15 CAR-T Cell Therapy Developers Distribution by Year of Establishment
Figure 4.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Figure 4.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18 CAR-T Cell Therapies: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 5.2 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Figure 5.3 CAR-Construction: Distribution by Generation of CAR
Figure 5.4 CAR-Construction: Distribution by Type of scFv Antibody
Figure 5.5 CAR-Construction: Distribution by Type of Virus Used
Figure 5.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 5.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 6.1 Clinical Trial Analysis: Scope and Methodology
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution of trials by Trial Registration Year, Pre-2013-2022
Figure 6.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2022
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 6.6 Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Figure 6.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 6.8 Clinical Trial Analysis: Distribution by Target Patient
Figure 6.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.10 Clinical Trial Analysis: Distribution by Study Design
Figure 6.11 Most Active Players: Distribution by Number of Registered Trials
Figure 6.12 Most Active Players: Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Key Focus Areas
Figure 6.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 6.15 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 6.16 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 6.17 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 7.1 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 7.2 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 7.3 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Figure 7.4 CAR-T Cell Therapies: Geographical Distribution of KOLs
Figure 7.5 CAR-T Cell Therapies Scatter Plot: KOL Activenes s versus KOL Strength
Figure 7.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 7.7 Most Prominent KOLs: Distribution by RA Score
Figure 7.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 7.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 8.1 Kymriah: Estimated Sales Revenues
Figure 8.2 Yescarta: Estimated Sales Revenues
Figure 8.3 Tecartus: Estimated Sales Revenues
Figure 8.4 Breyanzi: Estimated Sales Revenues
Figure 8.5 Abecma: Estimated Sales Revenues
Figure 8.6 Carvykti: Estimated Sales Revenues
Figure 8.7 Carteyva: Estimated Sales Revenues
Figure 8.8 AUTO1: Estimated Sales Revenues
Figure 8.9 AUTO3: Estimated Sales Revenues
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Figure 9.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 9.5 Partnerships and Collaborations: Distribution by Type of partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Figure 9.7 Most Popular Products: Distribution by Number of Partnerships
Figure 9.8 Most Active Industry Players: Distribution by Number of Partnerships
Figure 9.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 9.10 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Figure 9.11 Partnerships and Collaborations: Distribution of International and Local Deals
Figure 10.1 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Figure 10.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
Figure 10.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 10.5 Funding and Investments: Distribution by Types of Investors
Figure 10.6 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 10.7 Most Active Players: Distribution by Number of Instances
Figure 10.8 Most Active Players: Distribution by Amount Invested (USD Million
Figure 10.9 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 11.3 Patent Analysis: Cumulative Distribution Patent Application Year
Figure 11.4 Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 11.5 Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 11.6 Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Figure 11.7 Patent Analysis: Distribution by Geography
Figure 11.8 Patent Analysis: Distribution by Type of Player
Figure 11.9 Patent Analysis: Distribution by CPC Symbols
Figure 11.10 Patent Analysis: Key Focus Area
Figure 11.11 Leading Industry Players: Distribution by Number of Patents
Figure 11.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.14 Patent Analysis (Top 9 CPC Symbols): Benchmarking by Leading Players
Figure 11.15 Patent Analysis: Distribution by Patent Age
Figure 11.14 CAR-T Cell Therapies: Patent Valuation Analysis
Figure 12.1 Steps for Manufacturing Cell Therapies
Figure 12.2 Centralized Manufacturing: Process Model
Figure 12.3 Decentralized Manufacturing: Process Model
Figure 12.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 12.5 Cell Therapy: Challenges and Drivers
Figure 12.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 12.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 12.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 13.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 14.1 Global CAR-T Cell Therapies Market, 2022-2035 (USD Billion)
Figure 14.2 CAR-T Cell Therapies Market: Distribution by Target Indication(s), 2025 and 2035 (USD Billion)
Figure 14.3 CAR-T Cell Therapies Market: Distribution by Target Antigen(s), 2025 and 2035 (USD Billion)
Figure 14.4 CAR-T Cell Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 14.5 CAR-T Cell Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 14.6 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Figure 14.7 Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 14.8 Tecartus (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 14.9 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 14.10 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Figure 14.11 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 14.12 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.13 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.14 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.15 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.16 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.17 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Figure 14.18 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Figure 14.19 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.20 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Figure 14.21 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 14.22 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 14.23 CD19 CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 14.24 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, till 2035 (USD Million)
Figure 14.25 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.26 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2035 (USD Million)
Figure 14.27 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Figure 14.28 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Figure 14.29 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Figure 14.30 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.31 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, till 2035 (USD Million)
Figure 14.32 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.33 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.34 IC9-CAR19 T Cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Figure 14.35 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.36 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.37 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.38 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.39 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.40 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 14.41 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.42 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.43 WU CART 007 (WUGEN) Sales Forecast, till 2035 (USD Million)
Figure 14.44 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 15.1 Channels Used for Promotional Campaigns
Figure 15.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 15.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 15.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 15.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 15.6 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 15.7 Product Website Analysis: Yescarta, Messages for Patients
Figure 15.8 Product Website Analysis: Yescarta, Kite Konnect
Figure 15.9 Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 15.10 Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 15.11 Product Website Analysis: Tecartus, Messages for Patients
Figure 15.12 Product Website Analysis: Tecartus, Kite Konnect
Figure 15.13 Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 15.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 15.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 15.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 15.17 Product Website Analysis: Abecma, Messages for Patients
Figure 15.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 15.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 15.20 Product Website Analysis: Carvykti, Messages for Patients
Figure 15.21 Product Website Analysis: Carvykti, MyCARVYKTI
Figure 17.1 Concluding Remarks: Market Landscape
Figure 17.2 Concluding Remarks: Clinical Trial Analysis
Figure 17.3 Concluding Remarks: Key Opinion Leaders
Figure 17.4 Concluding Remarks: Partnerships & Collaborations
Figure 17.5 Concluding Remarks: Funding and Investment Analysis
Figure 17.6 Concluding Remarks: Patent Analysis
Figure 17.7 Concluding Remarks: Market Forecast

List Of Tables
Table 4.1 Biosensors in Drug Discovery: List of Companies
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.5 Key Characteristics of CAR-T Cells
Table 3.6 Comparison of First and Second-Generation CAR-Ts
Table 3.7 CD19 CAR-T Cells: Preclinical Results
Table 3.8 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 4.1 CAR-T Cell Therapies: Clinical Pipeline
Table 4.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 4.3 CAR-T Cell Therapies: Preclinical Pipeline
Table 4.4 List of CAR-T cells Developers
Table 5.1 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 8.1 CAR-T Cell Therapies: List of Therapies Profiled
Table 8.2 Therapy Profile: Kymriah® (Novartis)
Table 8.3 Kymriah: Clinical Trial Information
Table 8.4 Kymriah: Clinical Trial Endpoints
Table 8.5 Kymriah: Clinical Trial Results
Table 8.6 Therapy Profile: Yescarta (Gilead Sciences)
Table 8.7 Yescarta: Clinical Trial Information
Table 8.8 Yescarta: Clinical Trial Endpoints
Table 8.9 Yescarta: Clinical Trial Results
Table 8.10 Therapy Profile: Tecartus (Gilead Sciences)
Table 8.11 Tecartus: Clinical Trial Information
Table 8.12 Tecartus: Clinical Trial Endpoints
Table 8.13 Tecartus: Clinical Trial Results
Table 8.14 Therapy Profile: Breyanzi (Bristol Myers Squibb)
Table 8.15 Breyanzi: Clinical Trial Information
Table 8.16 Breyanzi: Clinical Trial Endpoints
Table 8.17 Breyanzi: Clinical Trial Results
Table 8.18 Therapy Profile: Abecma (Bristol Myers Squibb)
Table 8.19 Abecma: Clinical Trial Information
Table 8.20 Abecma: Clinical Trial Endpoints
Table 8.21 Abecma: Clinical Trial Results
Table 8.22 Therapy Profile: Carvykti (Janssen)
Table 8.23 Carvykti: Clinical Trial Information
Table 8.24 Carvykti: Clinical Trial Endpoints
Table 8.25 Carvykti: Clinical Trial Results
Table 8.26 Therapy Profile: Carteyva (JW Therapeutics)
Table 8.27 Carteyva: Clinical Trial Information
Table 8.28 Carteyva: Clinical Trial Endpoints
Table 8.29 Carteyva: Clinical Trial Results
Table 8.30 Therapy Profile: TBI-1501 (Takara Bio)
Table 8.31 TBI-1501: Clinical Trial Information
Table 8.32 TBI-1501: Clinical Trial Endpoints
Table 8.33 Therapy Profile: AUTO1 (Autolus)
Table 8.34 AUTO1: Clinical Trial Information
Table 8.35 AUTO1: Clinical Trial Endpoints
Table 8.36 AUTO1: Clinical Trial Results
Table 8.37 Therapy Profile: AUTO3 (Autolus)
Table 8.38 AUTO3: Clinical Trial Information
Table 8.39 AUTO3: Clinical Trial Endpoints
Table 8.40 AUTO3: Clinical Trial Results
Table 9.1 CAR-T Cell Therapies: List of Partnerships and Collaborations, 2005-2022
Table 10.1 CAR-T Cell Therapies: Funding and Investments, 2000-2022
Table 10.2 CAR-T Cell Therapies: Summary of Investments
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.1 Assessment Strategies for Different Manufacturing Processes
Table 12.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 12.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 13.1 Price of Marketed Gene / Cell Therapies
Table 13.2 Price of Marketed Targeted Drugs
Table 13.3 CAR-T Cell Therapies: Expert Opinions on Pricing
Table 13.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 14.1 CAR-T Cell Therapies: List of Forecasted Molecules
Table 14.2 Kymriah (Novartis): Net Present Value (USD Million)
Table 14.3 Kymriah (Novartis): Value Creation Analysis (USD Million)
Table 14.4 Yescarta (Gilead Sciences): Net Present Value (USD Million)
Table 14.5 Yescarta (Gilead Sciences): Value Creation Analysis (USD Million)
Table 14.6 Tecartus: (Gilead Sciences): Net Present Value (USD Million)
Table 14.7 Tecartus: (Gilead Sciences): Value Creation Analysis (USD Million)
Table 14.8 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Net Present Value (USD Million)
Table 14.9 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 14.10 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Net Present Value (USD Million)
Table 14.11 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Value Creation Analysis (USD Million)
Table 14.12 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Net Present Value (USD Million)
Table 14.13 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 14.14 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Net Present Value (USD Million)
Table 14.15 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Value Creation Analysis (USD Million)
Table 14.16 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 14.17 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.18 CD19 CAR-T (Wuhan Si'an Medical Technology): Net Present Value (USD Million)
Table 14.19 CD19 CAR-T (Wuhan Si'an Medical Technology): Value Creation Analysis (USD Million)
Table 14.20 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 14.21 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 14.22 Descartes-08 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 14.23 Descartes-08 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 14.24 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Net Present Value (USD Million)
Table 14.25 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Value Creation Analysis (USD Million)
Table 14.26 CNCT19 / HY001 (Juventas Cell Therapy): Net Present Value (USD Million)
Table 14.27 CNCT19 / HY001 (Juventas Cell Therapy): Value Creation Analysis (USD Million)
Table 14.28 CD30.CAR-T / TT11 (Tessa Therapeutics): Net Present Value (USD Million)
Table 14.29 CD30.CAR-T / TT11 (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 14.30 TAK-007 (Takeda): Net Present Value (USD Million)
Table 14.32 TAK-007 (Takeda): Value Creation Analysis (USD Million)
Table 14.33 AUTO1 (Autolus): Net Present Value (USD Million)
Table 14.34 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 14.35 AUTO3 (Autolus): Net Present Value (USD Million)
Table 14.36 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 14.37 CD19 CAR-T (Bioray Laboratories): Net Present Value (USD Million)
Table 14.38 CD19 CAR-T (Bioray Laboratories): Value Creation Analysis (USD Million)
Table 18.39 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.40 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.41 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 14.42 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 14.43 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD Million)
Table 14.44 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 14.45 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 14.46 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 14.47 CARCIK-CD19 (CoImmune): Net Present Value (USD Million)
Table 14.48 CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 14.49 PBCAR269A (Precision BioSciences / Servier): Net Present Value (USD Million)
Table 14.50 PBCAR269A (Precision BioSciences and Servier): Value Creation Analysis (USD Million)
Table 14.51 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 14.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 14.53 BCMA CAR-T (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 14.54 BCMA CAR-T (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 14.55 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 14.56 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.57 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Net Present Value (USD Million)
Table 14.58 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Value Creation Analysis (USD Million)
Table 14.59 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 14.60 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 14.61 ALLO-501A / ALLO-501 (Allogene Therapeutics): Net Present Value (USD Million)
Table 14.62 ALLO-501A / ALLO-501 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 14.63 CD19/CD20-CAR-T (Yake Biotechnology): Net Present Value (USD Million)
Table 14.64 CD19/CD20-CAR-T (Yake Biotechnology): Value Creation Analysis (USD Million)
Table 14.65 CD7 CAR-T (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 14.66 CD7 CAR-T (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 14.67 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 14.68 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 14.69 CT053 (CARsgen Therapeutics): Net Present Value (USD Million)
Table 14.70 CT053 (CARsgen Therapeutics): Value Creation Analysis (USD Million)
Table 14.71 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Net Present Value (USD Million)
Table 14.72 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 14.73 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 14.74 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 14.75 ALLO-605 (Allogene Therapeutics): Net Present Value (USD Million)
Table 14.76 ALLO-605 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 14.77 WU CART 007 (WUGEN): Net Present Value (USD Million)
Table 14.78 WU CART 007 (WUGEN): Value Creation Analysis (USD Million)
Table 14.79 CT103A (Nanjing IASO Biotherapeutics): Net Present Value (USD Million)
Table 14.80 CT103A (Nanjing IASO Biotherapeutics): Value Creation Analysis (USD Million)
Table 15.1 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Table 15.2 Kymriah: Drug Overview
Table 15.3 Yescarta: Drug Overview
Table 15.4 Tecartus: Drug Overview
Table 15.5 Breyanzi: Drug Overview
Table 15.6 Abecma: Drug Overview
Table 15.7 Carvykti: Drug Overview
Table 16.1 Leading CAR-T Cell Therapy Developers
Table 16.2 Autolus: Company Profile
Table 16.3 bluebird bio: Company Profile
Table 16.4 Bristol Myers Squibb: Company Profile
Table 16.5 CARsgen Therapeutics: Company Profile
Table 16.6 Cellectis: Company Profile
Table 16.7 Cellular Biomedicine Group: Company Profile
Table 16.8 Gilead Sciences: Company Profile
Table 16.9 Innovative Cellular Therapeutics: Company Profile
Table 16.10 Kuur Therapeutics: Company Profile
Table 16.11 Noile-Immune Biotech: Company Profile
Table 16.12 Novartis: Company Profile
Table 16.13 Shanghai Genechem: Company Profile
Table 16.14 Sinobioway Cell Therapy: Company Profile
Table 16.15 Takara Bio: Company Profile
Table 16.16 Wellington Zhaotai Therapies: Company Profile
Table 19.1 CAR-T Cell Therapies: Distribution by Type of Developer
Table 19.2 CAR-T Cell Therapies: Distribution by Phase of Development
Table 19.3 CAR-T Cell Therapies: Distribution by Target Therapeutic Area
Table 19.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Table 19.5 CAR-T Cell Therapies: Distribution by Key Target Indications
Table 19.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Table 19.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cell
Table 19.9 CAR-T Cell Therapies: Distribution by Route of Administration
Table 19.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Table 19.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Table 19.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Table 19.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 19.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 19.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Table 19.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 19.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 19.18 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 19.19 CAR-T Cell Therapies Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year
Table 19.20 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 19.21 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 19.22 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 19.23 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Table 19.24 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 19.25 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 19.26 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.27 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Study Design
Table 19.28 Most Active Industry Players: Distribution by Number of Registered Trials
Table 19.29 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 19.30 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 19.31 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 19.32 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 19.33 CAR-T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 19.34 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Table 19.35 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Table 19.36 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Table 19.37 CAR-T Cell Therapies: Geographical Distribution of KOLs
Table 19.38 CAR-T Cell Therapies Most Prominent KOLs: Distribution by RA Score
Table 19.39 CAR-T Cell Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 19.40 Kymriah: Estimated Sales Revenues
Table 19.41 Yescarta: Estimated Sales Revenues
Table 19.42 Tecartus: Estimated Sales Revenues
Table 19.43 Breyanzi: Estimated Sales Revenues
Table 19.44 Abecma: Estimated Sales Revenues
Table 19.45 Carvykti: Estimated Sales Revenues
Table 19.46 Carteyva: Estimated Sales Revenues
Table 19.47 AUTO1: Estimated Sales Revenues
Table 19.48 AUTO3: Estimated Sales Revenues
Table 19.49 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 19.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.51 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Table 19.52 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 19.53 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.54 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Table 19.55 Most Popular Products: Distribution by Number of Partnerships
Table 19.56 Most Active Industry Players: Distribution by Number of Partnerships
Table 19.57 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 19.58 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 19.59 Partnerships and Collaborations: Distribution of International and Local Agreements
Table 19.60 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Table 19.61 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 -2022 (USD Million)
Table 19.62 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 19.63 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 19.64 Funding and Investments: Distribution by Type of Investors
Table 19.65 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Table 19.66 Most Active Players: Distribution by Number of Instances
Table 19.67 Most Active Players: Distribution by Amount Invested (USD Million)
Table 19.68 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 19.69 Most Active Investors: Distribution by Number of Funding Instances
Table 19.70 Patent Analysis: Distribution by Type of Patent
Table 19.71 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 19.72 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 19.73 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 19.74 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 19.75 CAR-T Cell Therapies Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Table 19.76 CAR-T Cell Therapies Patent Analysis: Distribution by Geography
Table 19.77 CAR-T Cell Therapies Patent Analysis: Distribution by Type of Player
Table 19.78 CAR-T Cell Therapies Patent Analysis: Distribution by CPC Symbols
Table 19.79 Leading Industry Players: Distribution by Number of Patents
Table 19.80 Leading Non-Industry Players: Distribution by Number of Patents
Table 19.81 Leading Patent Assignees: Distribution by Number of Patents
Table 19.82 Patent Analysis: Distribution by Patent Age
Table 19.83 CAR-T Therapies: Patent Valuation Analysis

Companies Mentioned

  • 920th Hospital of Joint Logistics Support Force 
  • AbbVie Ventures
  • AbCellera
  • AbCheck
  • AbClon
  • Abound Bio
  • Abzena
  • Acabadem Atunizade Hospital
  • Acabadem Labcell
  • Acibadem University
  • ACROBiosystems
  • AdAlta
  • Adaptimmune Therapeutics
  • Adicet Bio
  • Adimab
  • Affiliated Hospital of Jiangnan University
  • Affiliated Hospital of Jiangsu University
  • Affiliated Hospital to Academy of Military Medical Sciences
  • Affiliated Zhongshan Hospital of Dalian University
  • AffyImmune Therapeutics
  • AGC Biologics
  • Agreen Biotech
  • AK (Suzhou) Biomedical
  • Alaunos Therapeutics
  • Aleta Biotherapeutics
  • Alexandria Venture Investments
  • Allife Medical Science and Technology
  • Allogene Therapeutics
  • Alpha Biopharma
  • Amgen Ventures
  • Anhui Anke Biotechnology
  • Anhui Provincial Hospital
  • Antion Biosciences
  • Appia Bio
  • Arbele
  • Arcellx
  • Astellas Pharma
  • Astrazeneca
  • Atara Biotherapeutics
  • August Pi and Sunyer Biomedical Research Institute
  • Aurora Biopharma
  • Autolus
  • Avencell
  • Bambino Gesù Hospital and Research Institute
  • Bayer
  • Baylor College of Medicine
  • Be The Match BioTherapies
  • Beam Therapeutics
  • Beijing 302 Hospital
  • Beijing Biohealthcare Biotechnology
  • Beijing Boren Hospital
  • Beijing Cancer Hospital
  • Beijing Chao Yang Hospital
  • Beijing Children's Hospital
  • Beijing Doing Biomedical
  • Beijing GoBroad Hospital Management
  • Beijing HuiNengAn Biotech
  • Beijing Immunochina Medical Science & Technology
  • Beijing Sanbo Brain Hospital
  • Beijing Tsinghua Chang Gung Hospital
  • Beike Biotechnology
  • Bellicum Pharmaceuticals
  • Beth Israel Deaconess Medical Center (BIDMC)
  • Bioceltech Therapeutics
  • Bio-Gene Technology
  • BioLife Solutions
  • Bionomics
  • BioNTech
  • Bioray Laboratories
  • Biosceptre
  • Bluebird Bio
  • Boya Jiyin
  • BoYuan RunSheng Pharma (Hangzhou)
  • Bristol-Myers Squibb
  • Cabaletta Bio
  • Cabaret Biotech
  • Calibr
  • California Institute for Regenerative Medicine (CIRM)
  • Cancer Prevention Research Institute of Texas
  • Cancer Research Technology
  • Cancer Research UK
  • Carbiogene Therapeutics
  • Caribou Biosciences
  • Carina Biotech
  • Caring Cross
  • Carisma Therapeutics
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • Cartherics
  • Case Comprehensive Cancer Center 
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cell Design Labs
  • Cellectis
  • Cellex Patient Treatment 
  • CELLforCURE
  • CellPoint
  • Cellular Biomedicine Group
  • Cellvec
  • Celularity
  • Celyad Oncology
  • Center for International Blood and Marrow Transplant Research
  • Central South University
  • Changhai Hospital
  • Chengdu USino Technology Biology
  • Children’s Hospital of Philadelphia
  • Children's Hospital and Health System Foundation
  • Children's Hospital of Fudan University
  • Children's Hospital of Philadelphia
  • China Immunotech (Beijing) Biotechnology
  • China Meitan General Hospital
  • China Regenerative Medicine International (CRMI)
  • Chinese Academy of Sciences
  • Chinese PLA General Hospital
  • Chongqing Precision Biotech
  • Chongqing Public Health Medical Center
  • Chongqing Sidemu Biotech
  • Chongqing University Cancer Hospital
  • City of Hope Medical Center
  • CoIMMUNE
  • Cold Spring Harbor Laboratory
  • Columbia University
  • CRISPR Therapeutics
  • Cryoport
  • CureSearch for Children's Cancer
  • Curocell 
  • CytoLumina Technologies
  • CytoMed Therapeutics
  • Cytovia Therapeutics
  • DAIICHI SANKYO COMPANY
  • Dana-Farber Cancer Institute
  • Dartmouth College
  • Delenex Therapeutics
  • DLR German Aerospace Center
  • Dongguan People's Hospital
  • East Clinical Center of Oncology
  • Eden BioCell
  • Editas Medicine
  • Eli Lilly
  • Elicera Therapeutics
  • Elpis Biopharmaceuticals
  • Eureka Therapeutics
  • Eutilex
  • EXUMA Biotech
  • Fate Therapeutics
  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology
  • Fidelity Management & Research
  • First Affiliated Hospital of Chengdu Medical College
  • First Affiliated Hospital of Harbin Medical University
  • First Affiliated Hospital of Wenzhou Medical Univeristy
  • First Affiliated Hospital of Wenzhou Medical University
  • First Affiliated Hospital of Zhejiang University
  • First Affiliated Hospital Xi'an Jiaotong University
  • First Hospital of Jilin University
  • First People's Hospital of Foshan
  • Five Prime Therapeutics
  • Fondazione Matilde Tettamanti Menotti De Marchi Onlus
  • Fondo Social La Caixa
  • Formula Pharmaceuticals
  • Fosun Pharmaceutical
  • Fourth Hospital of Hebei Medical University
  • Fraunhofer
  • Fred Hutchinson Cancer Research
  • Fred Hutchinson Cancer Research Center
  • Fudan University
  • Fujian Medical University
  • Fundamenta Therapeutics
  • FutureGen Biopharm
  • G Plus Life Sciences
  • GE Global Research
  • GE Healthcare
  • Genentech
  • Genus Oncology
  • Gilead Sciences
  • Glycostem
  • GlyTherix
  • Gracell Biotechnologies
  • Great Ormond Street Hospital for Children NHS Foundation Trust 
  • Guangdong General Hospital
  • Guangdong Zhaotai InVivo Biomedicine
  • Guangzhou 8th People's Hospital
  • Guangzhou Anjie Biomedical Technology
  • Guangzhou First People's Hospital
  • H. Lee Moffitt Cancer Center and Research Institute
  • Hadassah Medical Organization
  • Harvard University
  • HCW Biologics
  • Hebei Senlang Biotechnology
  • Hebei Yanda Ludaopei Hospital
  • Hefei Binhu Hospital
  • Heidelberg University Hospital
  • Henan Cancer Hospital
  • Henan Hualong Biotechnology
  • Henan Provincial People's Hospital
  • Hitachi Chemical Advanced Therapeutics Solutions
  • Horizon 2020
  • Horizon Discovery Group
  • Houston Methodist Hospital
  • Hrain Biotechnology
  • HuaDao (Shanghai) Biomedical
  • Huai'an Second People's Hospital
  • Huazhong University of Science and Technology
  • Hunan Provincial People's Hospital
  • Hunan Yongren Medical Innovation
  • Hunan Zhaotai Yongren Biotech
  • Hunan Zhaotai Yongren Medical Innovation
  • IASO Biotherapeutics
  • iCAR Bio Therapeutics
  • iCarTAB BioMed
  • iCell Gene Therapeutics
  • ICON
  • IIT MediTech (Jiangsu)
  • ImmunoACT
  • Imugene
  • Inhibrx
  • Innovative Cellular Therapeutics
  • Innovent Biologics
  • Institut Curie
  • Institute of Hematology & Blood Diseases Hospital
  • Institute of Hematology and Blood Transfusion
  • Instituto de Salud Carlos III
  • Intellia Therapeutics
  • Intrexon
  • Invectys
  • Janssen
  • Jiangsu Province Hospital of Traditional Chinese Medicine
  • Jiangyin People's Hospital
  • Jichi Medical University Hospital
  • Jingjiang People's Hospital
  • Jingzhou Central Hospital
  • Jonsson Comprehensive Cancer Center
  • Juno Therapeutics
  • Juventas Cell Therapy
  • JW Therapeutics
  • KAEDI
  • Karolinska Institute
  • Kecellitics Biotech
  • King's College London
  • Kite Pharma (a Gilead Sciences Company)
  • Kuur Therapeutics
  • Kyverna Therapeutics
  • Legend Biotech
  • Leucid Bio
  • Leukemia & Lymphoma Society
  • Leukemia Research Foundation
  • Life Technologies
  • Lilly Asia Ventures
  • Liminatus Pharma
  • Living Pharma
  • Lonza
  • Loyola University Medical Center
  • LUMICKS
  • Lyell Immunopharma
  • MabQuest
  • Malaghan Institute of Medical Research
  • Marino Biotechnology
  • Massachusetts General Hospital
  • MaSTherCell
  • Max Delbrück Center for Molecular Medicine 
  • MaxCyte
  • Mayo Clinic
  • MD Anderson Cancer Center
  • Medical College of Wisconsin
  • MedImmune
  • Medisix Therapeutics
  • MediTrust Health
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Mie University Hospital
  • Miltenyi Biomedicine
  • Miltenyi Biotec
  • Minerva Biotechnologies
  • Mink Therapeutics
  • Moderna
  • MolMed (acquired by AGC Biologics)
  • Mustang Bio
  • Nanfang Hospital of Southern Medical University
  • Nanjing Bioheng Biotech
  • Nanjing Children's Hospital
  • NantKwest
  • Nantong University
  • National Cancer Center Research Institute Japan
  • National Cancer Institute
  • National Heart, Lung and Blood Institute
  • National Institutes of Health (NIH)
  • National Institutes of Health Clinical Center
  • National Taiwan University Hospital
  • National University Hospital, Singapore
  • Navy General Hospital
  • NeoStem
  • Ningbo Cancer Hospital
  • NIPRO
  • Nkarta
  • Noile-Immune Biotech
  • Notch Therapeutics
  • Novartis
  • Novartis Venture Fund
  • nSAGE
  • NSF Engineering Research Center for Cell Manufacturing Technologies
  • Oncodesign Biotechnology
  • Oncora Medical
  • OncoTracker
  • Oncternal Therapeutics
  • Oncyte
  • ONK Therapeutics
  • oNKo-innate
  • ONO Pharmaceutical
  • Opus Bio
  • OrbiMed Advisors
  • Ospedale Pediatrico Bambino Gesù (OPBG)
  • Otsuka Pharmaceutical
  • Ottawa Hospital Research Institute
  • Outpace Bio
  • Overland Pharmaceuticals
  • Oxford Biomedica
  • Oxford Biotherapeutics
  • Oxford MEStar
  • panCELLa
  • Parker Institute for Cancer Immunotherapy
  • Pediatric Brain Tumor Consortium
  • Peking Union Medical College Hospital
  • Peking University People's Hospital
  • Peking University Shenzhen Hospital
  • Peking University Third Hospital
  • PeproMene Bio
  • PersonGen BioTherapeutics
  • Peter MacCallum Cancer Centre
  • Pfenex
  • Pfizer
  • PHARMALOG Institut für klinische Forschung
  • PhoreMost
  • Pieris Pharmaceuticals
  • Pierre Fabre
  • Pinze Lifetechnology
  • PLA General Hospital
  • Porton Biologics
  • Poseida Therapeutics
  • Precigen
  • Precision BioSciences
  • Pregenen
  • ProMab Biotechnologies
  • Protheragen
  • Qilu Hospital of Shandong University
  • RA Capital Management
  • Redmile Group
  • RedoxTherapeis
  • Refuge Biotechnologies
  • Regeneron Pharmaceutical
  • RenJi Hospital
  • resTORbio
  • Rockland Immunochemicals
  • Roger Williams Medical Center
  • Rosewell Park Comprehensive Cancer Center
  • Royal Adelaide Hospital Cancer Centre
  • Ruijin Hospital
  • Sabz Biomedicals
  • Sana Biotechnology
  • Sangamo Therapeutics
  • Sanofi
  • Scotia Biologics
  • Seattle Children’s Research Institute
  • Seattle Children's Hospital
  • Seattle Children's Research Institute
  • Second Affiliated Hospital of Guangzhou Medical University
  • Second Affiliated Hospital of Nanchang University
  • Second Affiliated Hospital of Suzhou University
  • Second Affiliated Hospital of Xi'an Jiaotong University
  • Second Military Medical University
  • Second Xiangya Hospital of Central South University
  • Servier
  • Shangai Cancer Institute
  • Shanghai Biomed-Union Biotechnology
  • Shanghai Bioray Laboratory
  • Shanghai Cell Therapy Group
  • Shanghai Changzheng Hospital
  • Shanghai Chest Hospital
  • Shanghai Children's Medical Center
  • Shanghai East Hospital
  • Shanghai GeneChem
  • Shanghai General Hospital
  • Shanghai International Medical Center
  • Shanghai Jiao Tong University School of Medicine
  • Shanghai Longyao Biotechnology
  • Shanghai Ming Ju Biotechnology
  • Shanghai OriginCell Therapeutics
  • Shanghai PerHum Therapeutics
  • Shanghai Pharmaceuticals
  • Shanghai Public Health Clinical Center
  • Shanghai Simnova Biotechnology
  • Shanghai Tong Ren Hospital
  • Shanghai Tongji Hospital
  • Shanghai Ultra-T Immune Therapeutics
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Shanghai Zhongshan Hospital
  • Shanxi Province Cancer Hospital
  • Shariati Hospital
  • Sheba Medical Center
  • Shenzhen Binde Biotechnology
  • Shenzhen BinDeBio
  • Shenzhen Children's Hospital
  • Shenzhen Geno-Immune Medical Institute
  • Shenzhen Hospital of Southern Medical University
  • Shenzhen Institute for Innovation and Translational Medicine
  • Shenzhen Second People's Hospital
  • Shenzhen University
  • ShiJiaZhuang Zhongxi Children Hospital
  • Shoreline Biosciences
  • Sichuan Kelun-Biotech Biopharmaceutical
  • Sichuan University
  • Simcere Pharmaceutical
  • Sinobioway Cell Therapy
  • Sistema and Russian Direct Investment Fund
  • Sorrento Therapeutics
  • Southern Medical University
  • Southwest Hospital
  • SpringWorks Therapeutics
  • St. Baldrick's Foundation
  • St. Jude Children's Research Hospital
  • Stage Cell Therapeutics
  • Stand Up To Cancer
  • Stanford University
  • Stony Brook University
  • Sun Yat-Sen University
  • Syncopation Life Sciences
  • Takara Bio
  • Takeda Pharmaceutical
  • TC BioPharm
  • TCRCure Biopharma
  • T-Curx
  • Tehran University of Medical Sciences
  • Tel Aviv Sourasky Medical Center
  • Temasek
  • Teneobio
  • Terumo BCT
  • Tessa Therapeutics
  • Texas Children's Hospital
  • The Affiliated Hospital Of Guizhou Medical University
  • The Affiliated Hospital of Xuzhou Medical University
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  • The Beijing Pregene Science and Technology
  • The Children's Mercy Hospital
  • The Faris Foundation
  • The First Affiliated Hospital of Anhui Medical University
  • The First Affiliated Hospital of Dalian Medical University
  • The First Affiliated Hospital of Guangdong Pharmaceutical University
  • The First Affiliated Hospital of Kunming Medical College
  • The First Affiliated Hospital of Nanchang University
  • The First Affiliated Hospital of Nanjing Medical University
  • The First Affiliated Hospital of Soochow University
  • The First Affiliated Hospital of University of Science and Technology of China
  • The First Affiliated Hospital of Zhejiang University
  • The First Affiliated Hospital of Zhengzhou University
  • The First Affiliated Hospital with Nanjing Medical University
  • The First People's Hospital of Changzhou
  • The First People's Hospital of Hefei
  • The First People's Hospital of Yuhang District
  • The First People's Hospital of Yunnan
  • The Fourth Hospital of Hebei Medical University
  • The General Hospital of Western Theater Command
  • The Ohio State University
  • The Pregene (ShenZhen) Biotechnology
  • The Second Affiliated Hospital of Chongqing Medical University
  • The Second Affiliated Hospital of Hainan Medical University
  • The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
  • The Second Hospital of Anhui Medical University
  • The Second Hospital of Hebei Medical University
  • The Second Hospital of Nanjing Medical University
  • The Seventh Affilliated Hospital
  • The Sixth Affiliated Hospital of Wenzhou Medical University
  • The Third People's Hospital of Kunshan
  • The Wistar Institute
  • ThermoFisher Scientific
  • Tianjin Medical University
  • Tianjin Medical University General Hospital
  • Tianjin Mycure Medical Technology
  • Ticaros
  • Timmune Biotech
  • Tiziana Life Sciences
  • Tmunity Therapeutics
  • Tongji Hospital
  • Tongji University
  • TrakCel
  • Transgene
  • Transposagen Biopharmaceuticals
  • TriArm Therapeutics
  • Trinity College Dublin
  • Tri-Service General Hospital
  • Triumph Over Kid Cancer Foundation
  • Tsinghua University
  • Twist Bioscience
  • TxCell
  • Ucello Therapeutics
  • UCL Business
  • UNC Lineberger Comprehensive Cancer Center
  • Union Stem Cell & Gene Engineering
  • United States Department of Defense
  • University College London
  • University Health Network
  • University of Alberta
  • University of Birmingham
  • University of California
  • University of Colorado
  • University of Milano-Bicocca
  • University of Minnesota
  • University of Munich
  • University of North Carolina
  • University of Pennsylvania
  • University of South Australia
  • University of Southern California
  • University of Texas
  • University of Washington
  • University of Washington and Seattle Cancer Care Alliance
  • University of Washington Cancer Consortium
  • University of Zurich
  • Uppsala University
  • USHEALTH
  • UTC Therapeutics
  • UWELL Biopharma
  • V Foundation
  • VCN Biosciences
  • venBio
  • Versant Ventures
  • Vineti
  • ViroMed
  • Vitruvian Networks
  • Vivo Capital
  • Washington University
  • Weill Cornell Medical College
  • Weill Medical College of Cornell University
  • Wellington Zhaotai Therapies
  • West China Hospital
  • West China Hospital of Sichuan University
  • Wugen
  • Wuhan Bio-Raid Biotechnology
  • Wuhan Sian Medical Technology
  • Wuhan Union Hospital
  • WuXi AppTec
  • X-Body
  • Xi'An Yufan Biotechnology
  • Xiangya Hospital of Central South University
  • Xiangyang Central Hospital
  • Xijing Hospital
  • Xinhua Hospital
  • Xinqiao Hospital
  • Xuanwu Hospital
  • Xuzhou Medical University
  • Yake Biotechnology
  • Yamaguchi University
  • Yan'an Affiliated Hospital of Kunming Medical University
  • Yunnan Cancer Hospital
  • Zhejiang Provincial People's Hospital
  • Zhejiang Qixin Biotech
  • Zhejiang University
  • Zhujiang Hospital

Methodology

 

 

Loading
LOADING...